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Summory
A technique has been developed to monitor the development of
thrombin in freshly collected whole blood in the absence of antico-
agulants. It is based on the centrifugai separation of the cellular
components from subsamples of blood drawn from non-anticoagulated
clotting whole blood which are diluted in buffer containing a
cluomogenic substrate.
It is shown that the burst of thrombin generation after triggering
coagulation with trace amounts oftissue thromboplastin occurs ooner
in non-anticoagulated whole blood than in citrated whole blood.
Heparin is shown to prolong the lagtime of thrombin generation more
in native blood than in recalcified citrated blood.
It is also demonstrated that intake of 500 mg of aspirin significantly
delays and inhibits thrombin generation in non-anticoagulated,
thromboplastin triggered whole blood, whereas it has no effect on the
coagulation i citrated plasma. The effect of aspirin intake on thrombin
generation i  blood is roughly equal to that of 0.03 U/ml of unfrac-
tionated heparin. This demonstrates that platelet reactions and the
coagulation system are closely linked processes. It furlher lends suppott
to the hypothesis that inhibition of thrombin generation is a common
denominator f antithrombotic therapy.
lnfroduclion
Thrombin is the central enzyme in the process of haemostasis, being
at the cross-roads of coagulation and platelet reactions. Measurement of
thrombin generation i  clotting plasma has provided much insight in
the mechanisms of action of the coagulation system (1). Moreover,
thrombin generation i platelet rich plasma (PRP) has proven useful in
studying the interplay of the plasmatic and the cellular factors in
coagulation (2). Measuring thb course of thrombin generation is a
better way to investigate generalised effects on coagulation than the
measurement of clotting times. Clotting is an early event, occuffing as
soon as 10-20 nM of thrombin are present in the system. It requires
less than l\Vo ofthe free thrombin that can be potentially generated in
plasma (150-300 nM). One can imagine that the extra thrombin
generated after coagulation in vivo will diffuse from the site of
coagulation and act in a haemostatic and/or prothrombotic manner e. g.
on platelets and other cells in the environment. Heparin e. g. has a well
established antithrombotic action and yet will not or hardly prolong
the thromboplastin time, i.e. the clotting time in the physiologically
* Present address: Department of Medicine, Division of Molecular Science,
Mount Sinai School of Medicine, I Gustave Levy Place, Box 1269, New York,
NY 10029, USA
Conespondence to: Dr. H. C Hemker, Cardiovascular Research
Institute Maastricht, Department of Biochemistry, Faculty II, Level 4,
University of Limburg, P. O. Box 616, 6200 MD Maastricht, The Netherlands
78
imporlant extrinsic system. It will have, however, a large effect on
the course of thrombin generation after clotting has occuned (3)'
Thrombin generation in PRP is nearer t0 physiology than that in
platelet poor plasrna (PPP). Yet, PRP is prepared from blood which
has been collected in citrate and is recalcified when coagulation is
triggered. This process of citration and recalcification, however, may
influence the function of platelets and the coagulation system. It is
known e.g. that perfusing the isolated rat heart with citrate and then
with a "recalcifying" Ringer solution is disastrous to heart ceils (4). In
an attempt 0 prevent he de- and recalcification step and to remain
as close as possible to the physiological circumstances, we developed
a technique for measuring ttrombin concentrations i  non-anticoagulat-
ed whole blood. The clotting process between assays was synchronised
by adding a very small amount of tissue thromboplastin. Erythrocytes
were discarded by centrifugation of subsamples diluted in buffer
containing achromogenic substrate. A comparison was made between
thrombin generation i  untreated whole blood, and citrated and subse-
quently recalcified blood.
The coagulation system and platelet activation are closely coupled.
Activated platelets provide the negatively charged phospholipid
surface necessary for various reactions of the coagulation system (5),
and thrombin is the most potent physiological activator of platelets.
Therefore, inhibition of platelet function may be expected to affect
thrombin generation. Acetylsalicylic acid (aspirin) inhibits platelet
function by ineversibly acetylating platelet cyclooxygenase (6). It
causes aprolongation of the bleeding time (7) and has been reported to
reduce the incidence of thromboembolic disease in several populations
at risk (8-11). However, no influence of aspirin on thrombin genera-
tion has as yet been demonstrated. This nevertheless would be expected
if indeed coagulation and platelet reactions are closely linked. We
thought hat this link might be severed by the preparation of PRP
(e.g. de- and recalcification) and investigated the possible effect of
aspirin on the coagulation system by measuring thrombin generation i
non-anticoagulated whole blood. We compared the effect to that of
heparin under the same circumstances.
It is our aim t0 present here the technique and to show that it may
be useful in the domain of the study of cell-coagulation system
interactions. Further studies on e. g. the aspirin effect will be necessary
and are being canied out in our laboratory.
Moleriols ond Melhods
Materials
Buffers used were 50 mM Tris-HCl, 100 mM NaCl and 0.5 g/l bovine
serum albumin, pH 7 9 (buffer B).
The 4th International standard heparin was obtained from the National
Bureau of Standards and Control (London). Enoxaparin was from Rhdne-
Poulenc-Rorer (Paris) The stable synthetic prostacyclin analog Ilomedine
(2K363'14) was from Schering AG (Berlin).
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Flg. 1 Time course of the haematocrit during clot formation. Blood from
a healthy donor was collected in a PVC tube without anticoagulant, and placed
in a waterbath at37'C. Thromboplastin (final dilution 1 to 3600) was added
exactly at I min after collection. Samples were drawn and processed for throm-
bin measurement asdescribed in the Materials and Methods section In addi-
tion, at two mrn intervals, 50 p"l of the mixture was transfened to empty PVC
tubes, from which heparinised haematocrit capillaries were filled. O-O
thrombin concentration Q-Q hasmnlssril
The haematocrit was measured in order to determine the volume of
plasma (Vo',.,n,). Any substance under investigation was added together with
0.25 Vpru,.o f buffer A In the control the same volume of buffer A only was
added
Step 2: Synchronisation of coagulation
Coagulation was tnggered, or rather synchronised (see results) by addition
of 0 25 Vproun, of buffer A containing 1/600 diluted thromboplastin (final
dilution 1/3600), This last addition was at exactly 1 min after collection of
blood but may be done at any time within 5 min after venipuncture.
Step 3r Subsampling and dilution of subsamples.
At timed intervals 10 pl subsamples were taken from the whole blood
mixture and transfened to tubes containing 190 pl buffer B with 200 pM of
the chromogenic substrate 52238. Within 10 s a second ilution was made by
transferring 40 pl of the obtained mixture to a microcentrifuge tube containing
760 pl buffer B, again containing 52238 (final concentration 200 pM) This
amounts to an overall dilurion of 1 in 400 of the original subsample. As soon as
the clot tended to interfere with subsampling, it was wound on a plastic spatula
and removed This appeared not to influence thrombin generation (data not
shown) The micro centrifugation tubes were kept on ice until subsampling had
finished.
Step 4: Centrlfugation The tubes with the diluted samples were centrifuged
for I min at high speed (Eppendorf centrifuge). Supematants were transfened
to disposable microcuvettes (05 ml) and prewarmed for at least 3 min at 37" C
Step 5: Thrombin determrnation
The rate of conversion of 52238 was determined photometrically at405 nm
by measuring optical density at two suitably spaced time points. The thrombin
concentration i the whole blood sample was calculated, knowing that 1 pM
thrombin causes 011mOD/min. as was determined with active sile{itrated
pure human a{hrombin The thrombin concentration was corrected for the
void volume occupied by the erythrocytes in the original subsample This void
volume decreases during the course of blood clotting. This was shown (Fig. 1 )
to be due only to cells getting entrapped in the clot. Thus, it seemed appro-
priate to use the initial haematocrit values for samples until clot formation, and
the final haematocrit values for samples tarting from clot formation. The lag
time of thrombin formation was determined as the time necessary to reach a
level of 50 nM of thrombin, as determined by linear interpolation. The mean
(n = 10) lag time of thrombin formation was 335 t 35s (s.e.), the mean
thrombin peak was 163 x25 nM (s.e.). Residual prothrombin was measured
after coagulation by measuring the increase in amidolytic activity induced by
adding an excess of staphylocoagulase (13).
Thrombin Generation i  Whole Blood Collected in Citrate
The procedure was completely identical to that described above, except hat
4.5 ml of blood were collected in 0.5 ml 0.13 M sodium citrate. Also the
additions were made in 0.25.Vpro,,u of buffer A without 2 mM CaCl2. At 1
min after collection coagulation was triggered by adding 0.25.V06,0 of throm-
boplastin diluted 1/600 (final dilution 1/3600) in buffer A containing 100 mM
CaCl (final added concentration 16.7 mM).
Thrombin Generation i  Platelet Rich Plasma
The procedure has been described in detail previously (2). Briefly, platelet
rich plasma (PRP) was prepared from citrated whole blood by centrifugation
(10 min, 1000 rpm).To240 p1 ofPRP were added 60 p"l ofbuffer A, and 60 pl
of 1/600 diluted thromboplastin (final dilution 1/3600) in 100mM CaCl,
(final added concentration I 67 mM). Thrombin generation was then monitored
by diluting timed subsamples in buffer B containing 200 pM 52238, and
assessing the 52238 conversion rate by an end-point measurement of optical
density.
Determination of Calcium Dependency of Clotting Times
Blood was collected in an empty PVC tube and immediately placed in a
waterbath. At registered times within 2 min after collection, 500 pl were added
to a tube containing 55 6 pl of trisodium citrate (0.13 M), 0.25.Vo,u,,0 of a
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Flg.2 Thrombin generation in non{riggered whole blood
?0
Blood from
a healthy donor was collected in an empty PVC tube at time zero and immedia-
tely placed in a waterbath at 37" C. At timed intervals amples, were drawn and
assessed for thrombin as described in the materials and methods ection
Chromogenic substrate for ttrombin was 52238 (H-D-Phe-Pip-
Arg-pNA.2HCl, from Kabi, Sweden)
Human brain thromboplastin was prepared as described by Owren (12).
It was subsequently centrifuged at 1000rpm for 5min and stored in 50pl
aliquots at -80" C It was thawed and diluted in buffer A containing 2 mM
CaCl, (for untreated whole blood) or containing 100 mM CaCl, (for blood
collected in citrate).
Subsequently, it was incubated at 37'C for 30 min before use Final
dilution after addition was 1 in 3600. Tenfold less diluted thromboplastin
produces aclotting time of 70 s in platelet poor plasma. Staphylocoagulase was
prepared and used as in ref. 13
Measurement oJ Thrombin Generation i  Non-anticoagulated Whole Blood
The measurement of thrombin generation was carried out in five steps:
Step 1: Venipuncture and preparation of the sample.
Blood was obtained by antecubital venipuncture. The first 2 to 3 ml were
discarded and then 4.5 ml were collected in a plastic tube on 0.5 ml buffer A,
not containing an anticoagulant, and immediately transfened to a water bath at
37" C. The buffer A was added to obtain a dilution of blood equal to that of
citrated b1ood.
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Flg. J Thrornbin generation i  whole blood triggered at a variable time after
collection Blood from a healthy donor was collected in an empty plastic tube at
time zero, and immediately placed in a waterbath at 37o C Thromboplastin (fi-
nal dilution 1 to 3600) was added 1 min (O), 3 min (O), 5 min E) or 7 min
(l) after collection At intervals, samples were drawn and processed for throm-
bin measurement asdescribed in the Materials and Methods ection. The oriSin
of the graph represents he moment of addition of thromboplastin
mlxture containing the desired CaCl, concentration, with or without | 2UlmI
of standard heparin (final concentration 0.2 U/ml), and 0.25 Voro,,o f 1/600
diluted thromboplastin (final dilution 1/3600) in buffer A. Also, 500 pl of
blood were added to a tube with 55.6 pi of buffer A containing 2 mM CaClt,
0.25'Vpr"uno of a mixture containing 2 mM CaClt, with or without 1 2 U/ml
of standard heparin (fina1 concentration 0 2 U/ml), and 0 25 Vpr",.u of 1/600
diluted tluomboplastin (final dilution 1/3600) in buffer A
Resulfs
Rationale of the Method
Calculation of the Plasma Volume
We wanted to express the amidolytic activity found experimentally
as the equivalent thrombin concenffation i  the plasma, so we needed to
cofiect for the (red) cell volume. To investigate whether this volume
changes during coagulation, we measured the haematocrit at timed
intervals during a thrombin generation experiment. Fig 1 shows that
the volume remains constant during the first few minutes, jumps to a
lower level at the time of clot formation, and then remains constant
again. Accordingly, the cell volume is routinely measured before and
after clotting. For calculation of thrombin concentrations, we used
the preclot value of the haematocrit until the moment hat 10 nM of
thrombin had formed, which is roughly equal to the moment of clotting,
and the postclot value afterwards.
Synchronisation f Coagulation between Experiments
In the non-anticoagulated biood that is collected, a slow intrinsic
initiation of the coagulation system will occur, resulting in clot
formation at variable times between 15 to 20 min after collection (when
PVC tubes are used), Several precautions were taken to minimize this
activation: The first 2 to 3 ml of blood collected were discarded in
order to minimise contamination with traces of tissue factor might from
the puncture wound. Additionally, the collected blood was pipetted
carefully and not mixed using vortex type mixers. In order to quantify
the extent of this activation of the coagulation system, we attempted to
measure thombin in non triggered whole blood during the first minutes
after collection, but concentrations remained below our detection limit
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Fig.4 Influence of the citrate/calcium ratio on the clotting times of whole
blood in the presence and absence of standard heparin. Blood from a healthy
donor was collected inan empty plastic tube, and immediately transfened to a
waterbath at 37' C. Clotting times were measured asdescribed in the Materials
and Methods section, after addition of drluted thromboplastin (1/3600), inthe
presence (O) or absence (O) of 0 2 U/ml of standard heparin The citrate/Ca2*
ratio was varied by adding different Ca2* concentrations to one citrate concen-
tration. Dotted lines: clotting times of non citrated whole blood with (upper
line) and without (lower line) 0.2 U/ml of standard hepann
for more then 10 min (Fig. 2). When triggered at 1 min after collection
with a trace amount of thromboplastin, the variance of the lag time had
disappeared largely and the coagulation process becomes ynchonised
between different experiments
Fig. 3 shows that the time delay between blood collection and
triggering coagulation with thromboplastin can be extended to 5 min
without a detectable influence on thrombin generation. Only when
thromboplastin was added at 7 min 0r more after collection, we
observed a slightly accelerated thrombin generation curye. Thus we
feel confident hat no detectable degree of activation has occuned
before triggering thrombin generation at I to 5 min. In all further
experiments, blood was triggered at exactly 1 min after collection.
Calcium Ion Concentrations
The optimal amount of Ca2* for recalcifying citrated whole blood
was determined by measuring the clotting times of citrated whole blood
recalcified with different Ca2* concentrations, in the presence and
absence of standard heparin (0.2 U/m1, final concentration). Fig.4
shows the existence of a relatively broad Ca2* optimum. The figure
also shows that no citrate "calcium" ratio can rival non-anticoagulated
whole blood with regard to sheer speed of clotting. Both in citrated and
in non-citrated blood the residual prothrombin concentrations as
measured with the aid of staphylocoagulase wasless rhan 0.5%, r.e.
significantly less than the l\Va of residuai prothrombin that is usually
observed when PPP is clotted with thromboplastin (13).
Treatment of the Subsamples
Upon subsampling thrombin formation is halted by the presence of
EDTA in the buffer. At the same time the chromogenic thrombin
substrate 52238 competitively inhibits the calcium-independent
binding of thrombin to protease inhibitors. We measured that the rate of
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Fr-e ,; Thombin generation i  untreated and citrated whole blood, effect of
.randard heparin and the low molecular weight heparin enoxaparin Blood fiom
a healthy donor was collected both on citrate, and in an empty plastic tube Both
were transfened to a waterbath at 37" C Standard heparin (upper graph, final
concentrations 0 [O], 0.1 [n] or 0.2 [A] U/ml) or enoxaparin (lower graph,
final concentrations 0 (O) or 1 (n) pg/ml was added. Clotting was triggered by
addition ofthromboplastin (1i3600 final dilution), at exactly 1 min after collec-
tion for the untreated whole blood, and at I min 30 s for the citrated whole
blood The expenment was run in separate series. one for each heparin concen-
tration, on the same day with the same donor Thrombin generation t  untreated
(closed symbols) and citrated (open symbols) whole blood rvas measured in
parallel
Table I Effect of aspirin on thrombin generation
Lag-time of thrombin generation (s t s e m )
before aspirin alter aspirin
chromogenic substrate conversion remains constant until the absor-
bancy at 405 nm exceeds 0.9 OD units. Under our conditions this
allows for a centrifugation step before measuring amidolytic activity.
With a 400-fo1d ilution, as used during our experiments, one typically
obtains a maximum amidolytic activity of n0 more than 30 mOD/min,
which means that we have about 30 min of constant reaction rate.
Effects of Heparin
We investigated whether the effect of unfractionated heparin and a
low molecular weight heparin (Enoxaparin) would be the same in
native blood and in recalcified citrated blood. The results are shown in
Fig. 5. In the upper pansl, we show three pairs of generation curves in
which we compare the effect of 0, 0.1 and 0.2 U/ml of unfractionated
heparin in citrated (open symbols) and native whole biood (closed
symbols). Blood was collected three times from the same volunteer,
each time in parallel in citrate and in buffer A. The lower panel of
Fig 5 shows a similar experiment, performed with and without 1 pg/ml
of enoxaparin The lag phase between triggering and the burst of throm-
bin generation was always shorter in untreated whole blood than in
citrated whole blood. Increasing concentrations of heparin cause a lag
time that is progressively longer in citrated whole blood than in non-
citrated whole blood. The heparin induced inhibition of the peak
t ime (min)
Flg.6 Influence of Ilomedine on thrombtn generation i  non-anticoagulated
whole blood and platelet rich plasma Upper panel: Whole blood. Blood liom a
healthy donor was collected both on Ilomedine (O) (100 pM, 9 vol blood on
I vol of llomedine) and in an empty plastic tube (O), and placed on a water bath
at 37" C Clotting was triggered by addition of thromboplastin (1/3600 final
dilution) exactly at I min after collection Lower panel: PRP. Blood from the
same donor was collected both on citrate (O), and on citrate/llomedine (O).
PRP was prepared as described in the materials and methods section, and
placed in a water bath at 37" C. Clotting was triggered by addition of thrombo-
plastin (1/3600 final dilution). In both cases thrombin concentrations were
measured as described in the Materials and Methods ection
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paired t-test (two-tailed)
t = 4 . 5 3 , P < 0 . 0 0 5
paired t-test (two-tailed)
t = 2 4 6 , P < 0 . 0 5
before aspirin
1 6 3 t 8
after aspirin
l4T x6
The time course of thrombin concentrations (n = 10) was measured in non-
anticoagulated whole blood, 5 min before and 1 5 h after intake of 500 mg
acetylsalicylic acid The lag of thrombin generation defined as the exact ime
when 50 nM of thrombin had formed, was determined by linear interpolation
from sunounding data points Data were evaluated using Student's t-test for
paired observations (two-tailed).
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amount of thrombin appears more important in non-anticoagulated
blood than in recalcified biood.
The Effect of Aspirin onThrombin Generation
The effect of intake o[ a single dose of 500 hg of aspirin on tluom-
bin generation in whole blood was investigated in 10 healthy male
volunteers, none of whom had taken any medication for at least one
week. Samples for determination of thrombin generation in non-
anticoagulated whoie blood, were taken 5 min before, and 1.5 h after
aspirin ingestion. Thrombin generation appeared tobe both delayed and
dimrnished 1.5h after aspirin intake (Table i). The average increase
of the lag time,3l s t 8 (SEM). was statistically significant (p <0.005,
t-test for paired observations, two tailed) Inhibition of thrombin peak
values of thrombin generation after aspirin was significant as well
(16 nM t 6, p <0.05).
In order to determine the maximal effect 0n thrombin generation i
whole blood that can be obtained by inhibiting blood platelets, we
collected blood in 10 pM (final concentration) of the stable synthetic
prostacyclin analog Ilomedine (2K36374). Platelets from blood
collected in Ilomedine did not aggregate after addition of collagen.
Blood was also collected incitrate and Ilomedine to assess the effect of
Ilomedine in platelet rich plasma. In five different experiments we saw
that both in non-anticoagulated whole blood and in platelet nch plasma
Ilomedine caused a small (2 min) delay of thrombin generation. In
nrrn-enticoagulated blood the amount of thrombin generated was
redu;ed by about 157o whereas the inhibition in PRP was much larger.
Fig. 6 shows a typical experiment.
Discussion
It is common practice to study the thrombin generating system in
platelet poor plasma. This indeed is the best way to investigate the
interplay of factors in the soluble plasmatic oagulation system In the
blood however this system does not act in splendid isolation, but in the
presence of blood cells. It becomes more and more clear that there are
many connections between the thrombin-generating system of plasma
and blood platelets and other blood cells. It therefore may be useful to
compare thrombin generation i  PPP to thrombin generation i  whole
blood. If citrated blood is used, then the platelets and other cells go
through a period oflow ambient Ca2* concentration. It has been shown
that this procedure in the isolated perfused rat heart induces important
changes inceli reaction and viability (see 4 and references therein). One
would therefore like to study whole blood in a setup where no transient
changes of Ca2* concentration have occuned. This amounts to
investigate freshly drawn blood. Such blood must be thought o be
triggered immediately upon venipuncture. It is evident fiom our results
that the addition of a fixed low concentration f tissue factor at between
I and 5 min after venipuncture makes it independent of suboptimal
triggering occurring upon venipuncture and synchronises the clotting
process in different experiments.
Apart from developing the experimental system, in this study we
did preliminary experiments o see whether the effect of heparin and
platelet inhibitors would be different in non anticoagulated whole blood
and in citrated and recalcified whole blood.
Heparin
Comparison of thrombin generation i the absence and presence of
heparin in citrated whole blood with thrombin generation in platelet
rich plasma in a similar experimental system, as measured by B6guin et
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al. (2) showed litt1e differences both in 1ag times and in peak thrombin
concentrations (results not shown). In contrast to this, we observed that
the burst of thrombin generation occurs earlier after triggering in blood
without added anticoagulant. Furthermore, the influence of heparin on
the lag time of thrombin generation isconsiderably smaller in untreated
whole blood than in recalcified citrated whole blood but the inhibition
of the peak amount of thrombin appears larger. Fig. 4 shows that thts
effect is not due to a suboptimal citrate to calcium ratio in the case
of citrated whole blood. It may be related directly to the presence of
c1ffate.
There are several conceivable ffects of citrate on the clotting
process. Citrate is a weak Ca2* buffer, since it binds Ca2* with a
relatively low affinity (Kd = 0.25 mM, 14). Moreover, Mg2* is bound
by citrate with equal affinity, resulting in a decreased concentration of
free M92* after recalcification, which may affect platelet function. Also,
citrate may slightly increase the pH of the reaction mixture. Ftnally, a
direct effect of citrate on platelet procoagulant or heparin scavenging
functions may not be excluded. It is therefore conceivable that the
presence of citrate modifies thrombin generation when platelets
participate in the process.
It must be stressed that our results pertain to heparin added to the
blood after venipuncture. It is pianned to determine the effects of the
administration (lV and SC) of (unfractionated- and 1ow molecular
weight-) heparin to volunteers. The main effect o be expected is that in
low molecular weight heparins the very low molecular weight material
that is resistant to pf4 action will be relatively enriched in the later
hours of heparin action, due to the longer half life time of these heparin
molecules (15).
Aspirin
Classically a distinction is made between arterial thrombosis and
primary haemostasis which are viewed as predominately platelet
mediated processes, and venous thrombosis and secondary haemostasis
where the coagulation system plays the major role. Yet recent insights
tend to stress the importance of thrombin in the pathogenesis of arterial
thrombosis (16-17) and major clinical ffials show that anticoagulant
drugs such as heparin and oral anticoagulants, are effective anti-
thrombotics not only in the venous but also in the arterial circulation
(1 8-20). This suggests hat affecting the concentration f free thrombin
may be a shared mechanism of action of anti-thrombotic drugs. On
the other hand aspirin has been reported to reduce the incidence of
thromboembolic disease in several populations at risk (8-1 1). Its mode
of action is understood to be the ineversible acetylation of platelet
cyclooxygenase. The blood coagulation system has not generally
been thought o be involved in its antithrombotic and bleeding time
prolonging effect.
This might be thought o refute the hypothesis of a central role
of thrombin. In the body however thrombin generation and platelet
activation are strongly interlinked. It therefore is a logical question to
ask whether, in a more integrated system such as whole blood, platelet
inhibition and thrombin generation are coupled or not.
Our observation that aspirin intake delays and inhibits thrombin
generation i non-anticoagulated whole blood opens the possibility that
aspirin indeed (partially) acts via its influence sn thrombin generation.
The two explanations are not mutually exclusive because inhibition of
cyclooxygenase may be the cause of the anticoagulant effect and/or
may have additional effects independent of coagulation. Anyhow the
cyclooxygenase inhibition must be thought o be maximally present
1.5 h after aspirin ingestion, i.e. the moment hat we took the second
blood sample (21). The extent of the effect is comparable to that of a
moderate concentration (0.03 lUiml) of unfractionated heparin. We
found no effect of aspirin in citrated blood or platelet rich plasma. A
similar effect of aspirin on coagulation i  non-anticoagulated whole
blood in an otherwise completely different experimental system was
recently observed by Basic-Micic et al. (22). Furthermore, Kyrle et al.
showed that fibrinogen peptide A concentrations in blood fiom
bleeding time wounds were decreased after aspirin treatment (23).
An estimate of the maximal effect on thrombin generation i whole
blood and platelet rich plasma that can be caused by platelet inhibition
was obtained by collecting blood on Ilomedine (final conc. 10 pM).
This substance in this concentration is known to completely inhibit
platelet activation by thrombin (24). Ilonedine causes a relatively small
delay of thrombin generation (about 2 min). Both in PRP and in whole
blood, a reduction of the amount of generated thrombin was observed.
The effect was much more important in PRP than in whole blood,
which may possibly be attributed to the presence of erytluocytes.
Anyhow, addition of the leucocyte fraction to PRP had no effect on
tkombin generation and its inhibition by Ilomedine (results not shown).
We must conclude that inhibiting platelets i  a relatively inefflcient way
to inhibit overall thrombin generation i experimental systems uch as
the one we used. The effect of aspirin must be considered as being
of the same order as that of Ilomedine. The modest maximal effect
attainable by platelet inhibition will make that the influence of aspirin
on thrombin generation iseasily overlooked.
The observation that inhibitors of platelet function, such as aspirin,
do affect hrombin generation i non-anticoagulated whole blood, lends
support 0 the notion of a common pathway for the various sorts of
anti-thrombotic therapy. Reduction of thrombin concentrations, then,
may be achieved by inhibition of thrombin formation (e.g. oral
anticoagulation), by increase of thrombin inactivation (e. g. heparin) or
by inhibition of platelet function (e. g. aspirin). We do not claim that the
observed inhibition of thrombin inhibition completely explains the
antitluombotic action of aspirin but we want to suggest that it contri-
butes t0 it. Further studies e.g. on dose dependency, duration ofthe
effect etc. will be necessary.
In conclusion, a precise chromogenic measurement of thrombin
generation in whole blood samples is feasible using the technique
presented here. Collection of blood in citrate appears t0 cause a delay
and diminution of thrombin formation and causes the effect of
heparin to be overestimated. In addition a delaying and inhibiting effect
of aspirin ingestion on thrombin generation can been demonstrated in
whole blood only, stressing the linkage between platelet reactions and
coagulation. We are aware of the fact that the reported phenomena
pose more questions than they answer and that much more work has
been done to precisely define the pharmacokinetics of this aspect of
heparin and aspirin action.
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